ÖSEL DEVICES › Cover
1 / 12
SME Gems · Hidden Champions Of The SME Platform
ÖSEL DEVICES LIMITED
From LED Displays & Hearing Aids to India's Exclusive Philips Mobile Partner
Market Cap
₹899 Cr
Updated
CMP
₹508
NSE SME
TTM Revenue
₹246 Cr
FY25 Full Year
3Y PAT CAGR
111%
FY22–FY25
📺
LED Display Systems
Core revenue engine
48.9%
H1 FY26 Revenue Mix
🎧
Hearing Aid Devices
MD-5 certified · highest margins
35.2%
H1 FY26 Revenue Mix
📱
Mobile Phones & Tablets
Exclusive Philips India licensee
15.9%
H1 FY26 Revenue Mix
⚠NSE SME: OSELDEVICE · March 2026 · For Educational Purposes Only — Not Investment Advice
02 · Company Snapshot
At a Glance
ÖSEL Devices Limited · NSE SME: OSELDEVICE · Founded 2006
Founded in 2006, Osel Devices is a Greater Noida–based technology manufacturer of LED display systems and hearing aids. Listed on NSE SME in September 2024, it has since added two major growth vectors: exclusive Philips Mobile brand rights for India, and the acquisition of SFL Hearing Solutions. The company now spans three verticals — LED Displays, Hearing Aids, and Mobile Phones.
Market Cap
₹899 Cr
Updated
CMP
₹508
NSE SME
52W Hi / Lo
₹835 / ₹197
NSE Data
Listed
Sep 2024
IPO ₹160
Stock P/E (TTM)
~33x
MCap/PAT ~₹27Cr
Book Value/Share
₹100
Per Share
ROE
30.1%
FY25
ROCE
31.1%
FY25
H1 FY26 Highlights
Revenue
₹147 Cr
+68% YoY
EBITDA
₹25 Cr
Margin 17%
PAT
₹15 Cr
+89% YoY
EPS (H1)
₹9.27
vs ₹4.97 prior
3Y Rev CAGR
42%
FY22–FY25
3Y PAT CAGR
111%
FY22–FY25
03 · History & Management
The Osel Story — 2006 to 2026
2006
Founded — LED Display Manufacturer
Incorporated as Innovative Infratech Solutions in Greater Noida. Core: LED display design and installation.
2020
Hearing Aids Vertical
Diversified into hearing aids. Secured the rare MD-5 medical device certification.
Sep 2024
NSE SME IPO — ₹160
Listed at ₹198.5 vs. issue price ₹160. Earkart MoU signed on day one.
Jul 2025
Preferential Issue — ₹55 Cr @ ₹340
₹55 Cr raised at ₹340/share. Mukul Agrawal enters at 7.56%.
Aug 2025
Philips Mobile — Exclusive India License
Exclusive brand license via TPV. Feature phones launched with Zenotel as national distributor.
Mar 2026
SFL Acquisition — ₹30 Cr
Osel Healthcare acquires 90.69% of SFL Hearing Solutions — India's largest multi-brand hearing clinic chain.
Apr 2026
US FDA Registration
Greater Noida hearing aid facility successfully registers with the US FDA, unlocking the massive US medical device market for high-margin exports.
IPO Price
₹160
Current CMP
₹508
Return from IPO
+218%
"Exponential" growth commentary in Jan 2026 — unusually bold for conservative management. Signals real FY27 conviction.
Key Management
Promoter & MD
Ravi Shanker Mishra
Founder-visionary; drove 3-vertical platform strategy. "Exponential" growth commentary in Jan 2026 signals real confidence in FY27 delivery.
Whole-Time Director
Mukesh Kumar Sinha
Day-to-day operations & investor relations. Manages working capital discipline across project-based business cycles.
New CEO (Mobile)
—
Ex-CEO, Vodafone North India
Last-mile telecom distribution DNA; Jio & Airtel relationships critical to Philips phone scale-up.
LED & Defence Consultant
—
Ex-Doordarshan Executive
Strong broadcast sector connects; overseeing defence LED supply. ₹50 Cr Army tender bid submitted.
04 · Business Segments
Three Verticals — One Platform
MGMT Target Mix FY26: Medical ~20% · LED ~30% · Philips Mobile ~30% · OEM LED ~20%
📺 LED Display Systems
Core
48.9%
- End-to-end: design to installation
- Indoor, outdoor, video walls, fine-pitch LED
- Clients: DRDO, NBCC, IndusInd, PVR, Levi's
- OEM manufacturing for MNC brands
- 99% YoY segment growth H1 FY26
- JNPT free zone — Middle East & US exports
- ₹50 Cr Army tender bid submitted
Gross Margins: ~15–20%
🎧 Hearing Aid Devices
OEM
35.2%
- 4,00,000 units p.a. production capacity
- MD-5 certified — rare regulatory moat
- BTE, ITE, CIC, IIC, RIC, ITC range
- Govt tenders (ADIP scheme) — core B2B
- Earkart retail + audiologist network
- SFL acquisition — full-stack hearing vertical
- US FDA Registered (Apr 2026)
- Export ready for high-value US market
Gross Margins: ~30–35% (Highest)
📱 Mobile Phones & Tablets
New Engine
15.9%
- Exclusive Philips brand license (via TPV)
- Phase 1: Feature phones — 90Mn unit market
- Phase 2: Smartphones — ₹4L Cr market
- 1L pilot → 3L order → targeting 5L+ units
- 120+ distributors, 650+ service centres
- Ex-Vodafone CEO — Jio & Airtel channel
- Smartphone announcement imminent
Target EBITDA: 15–20%
05 · LED Display Systems
Core Revenue Engine — Now Going Global
India LED Display Market
2024 Market Size
$0.81 Bn
2033 Forecast (IMARC)
$1.30 Bn
+60% growth runway
OSEL's LED Strategy
Bank Tie-Ups — Bulk LED installations across branch networks nationwide. One client, multi-location rollout.
JNPT Facility — 5 acres at JNPT free zone. Middle East & US exports once tariffs stabilise.
International OEM — Manufacturing for global LED brands. OEM revenue stream at scale.
Defence Contracts — Supplied border surveillance screens. ₹50 Cr Army tender bid; new Defence hire onboard.
Key Demand Drivers
→ Retail & hospitality digital signage
→ DOOH advertising boom
→ Command & control centres (Govt + Defence)
→ Banking nationwide digital rollouts
Key Institutional Clients
DRDONBCCIndusInd BankPVR CinemasLevi'sAdidasRadoSharda UniversityLulu MallIndia TVCentre for SightWorldmark
06 · Hearing Aid Vertical
Regulatory Moat · Highest Margins · Entering Retail
India Hearing Aid Market
2024 Market
$235 Mn
2033E Market
$376 Mn
India Reality: 1.3 Bn people · ~7% affected · <0.5% treated — massive gap
Market Size: Only 700K hearing aids sold vs. 91 Mn in need annually
Global: 488 Mn affected worldwide; <10% adoption — chronic underserved
Earkart — Key Distribution Partner
On listing day (Sep 2024), Osel signed an MoU appointing Earkart Pvt. Ltd. as exclusive retail hearing aid distributor across India for 2 years — instantly converting from pure B2B to B2C retail overnight.
OSEL's Position & Strategy
MD-5 Certified — One of India's rarest medical device licences
4L Units/yr — 4,00,000 hearing aids p.a. capacity
Tiered Portfolio — Basic ₹10K–30K · Mid ₹30K–1L · Premium ₹1L–4L
Tech Partner — Frye Electronics USA — clinical-grade calibration
Audiologist Net — Building nationwide clinical ecosystem
US FDA Registered — Greater Noida facility secured FDA registration (Apr 2026), unlocking direct access to the high-value US medical device market for export-led growth.
Govt Push — ADIP scheme subsidises devices — OSEL key beneficiary
Global Competition — "The Big 5"
Sonova/Phonak — Swiss · Largest globally · Premium
Starkey Labs — US · AI hearing aids · ENT connect
Siemens/Signia — German · Wide range · Audiologist fav.
Amplifon — Italian · Retail chain · Pan-India stores
OSEL competes on price + govt channel; retail brand gap remains.
07 · Mobile Phones & Tablets
India's Exclusive Philips Mobile Partner
Market Entry, Competitive Edge & Philips Partnership
The Philips Partnership
→ Exclusive Sales & Promotion Rights via TPV — Philips' official brand licensee
→ OSEL owns manufacturing, marketing & distribution end-to-end (full P&L)
→ Zenotel India: national distributor · 700+ distributors · 1L+ retailers targeted
→ Ex-Vodafone CEO hired — last-mile telecom channel reach & Jio/Airtel connects
Phase 1 — NOW LIVE
Feature Phones
- Market: ₹10,000 Cr/yr · 90 Mn units
- Pilot 1L → Order 3L → Target 5L+
- 120+ distributors · 650+ service centres
- 15–20% EBITDA target
Phase 2 — UPCOMING
Smartphones
- Market: ₹4,00,000 Cr · 170 Mn units
- Announcement imminent
- Philips brand locks users before migration
OSEL's Competitive Edge
Brand Heritage — 150+ yrs of global trust vs. Chinese no-names
Distribution Speed — 120 distributors + 650 service centres in 4 months
Telecom Channel — Ex-Vodafone CEO; Jio & Airtel preinstall network
Full P&L Control — Manufacturer + marketer + distributor
Smartphone Ladder — Feature phone DNA retains users for Phase 2
FY27 Conviction — "Exponential growth" — unusually bold for conservative mgmt
Feature Phone Market — Key Players
JioPhone
~30%
Samsung
~18%
Nokia (HMD)
~15%
itel / Tecno
~12%
Lava / Karbonn
~8%
Philips (OSEL)
Entry
08 · Osel Healthcare — Subsidiary & Acquisition
Acquiring SFL Hearing Solutions
Deepening the Healthcare Vertical — NSE Filing, 24 Mar 2026
Acquirer
Osel Healthcare Pvt. Ltd.
(100% subsidiary of Osel Devices)
(100% subsidiary of Osel Devices)
Target
SFL Hearing Solutions Pvt. Ltd.
Stake Acquired
90.69%
Consideration
₹30 Crore
Seller
U & N Enterprises Pvt. Ltd.
Related Party?
No — Arm's Length
Nature
Share Purchase Agreement (SPA)
Parent Impact
No change in management or control of Osel Devices Ltd.
Rights Obtained
Board nomination, affirmative voting, preemption, anti-dilution protection
Strategic Rationale
SFL operates in hearing solutions — directly complementary to Osel's manufacturing & Earkart's retail distribution
At ₹30 Cr, affordable scale-up in the highest-margin segment (hearing aid gross margins 30–35%)
SFL's network + Earkart + audiologist programme = full-stack hearing vertical
India hearing aid treatment rate <0.5% of affected population — massive runway ahead
FY26 Impact
Negligible. SPA signed 24 Mar 2026; closing expected Q1 FY27.
FY27 Contribution (Est.)
₹22–25 Cr
Topline · ~₹5–6 Cr incremental PAT
Post-Acquisition Structure
ÖSEL DEVICES LIMITED (Listed · OSELDEVICE)
└── Osel Healthcare Pvt. Ltd. (100% subsidiary)
└── SFL Hearing Solutions (90.69%) — FY27 onwards
└── Osel Healthcare Pvt. Ltd. (100% subsidiary)
└── SFL Hearing Solutions (90.69%) — FY27 onwards
09 · Financial Performance
FY21–FY25 Audited · H1 FY26 Unaudited
Revenue (₹ Cr) · FY21–H1 FY26
* H1 FY26 only — annualised run-rate ~₹300 Cr
| Period | Revenue (₹ Cr) | EBITDA (₹ Cr) | OPM% | PAT (₹ Cr) | EPS (₹) |
|---|---|---|---|---|---|
| FY21 | 57 | 3 | 5% | 1 | — |
| FY22 | 65 | 5 | 8% | 2 | — |
| FY23 | 82 | 8 | 10% | 5 | — |
| FY24 | 132 | 18 | 14% | 13 | — |
| FY25 | 186 | 33 | 18% | 20 | — |
| H1 FY25 | 87 | 13 | 15% | 8 | 4.97 |
| H2 FY25 | 99 | 20 | 20% | 12 | 7.46 |
| H1 FY26 | 147 (+68% YoY) | 25 | 17% | 15 (+89% YoY) | 9.27 |
| FY26E (Full Year)* | ~300 Cr | ~52 Cr | ~17% | ~35 Cr | — |
* FY26E based on H1 FY26 run-rate + management guidance. Not a formal forecast. Conduct your own analysis.
⚠ Working Capital Watch: Receivable days 73→128 (FY24→FY25). Working capital days 38→163. Government project cycles extend to 120+ days. Cash conversion cycle widening is the key operational watch point.
10 · Stock Performance · Valuation · Key Investors
Where ÖSEL Trades
At ₹508 CMP / ₹899 Cr MCap — Institutional-Like Conviction
NSE SME Price Journey — Sep 2024 to Mar 2026 (Indicative)
TTM P/E
~33x
MCap ₹899Cr / TTM PAT ~₹27Cr
Fwd P/E FY26E*
~25.7x
MCap / FY26E PAT ~₹35 Cr
Fwd P/E FY27E†
~15.6x
MCap / FY27E PAT ~₹55–60 Cr
MCap / Sales
3.65x
TTM Revenue ₹246 Cr
* FY26E PAT ~₹35 Cr: H1 run-rate estimate. Not a formal forecast. † FY27E PAT ~₹55–60 Cr: Indicative only. Not investment advice.
Key Investors
MA
Mukul Mahavir Agrawal
7.56% stake
Pref Sep 2025 · 6-month lock-in lapsed Mar 2026 — no supply has hit market. Signals conviction in future delivery.
HG
Hemant Gadodia (Invicta)
1,00,000 warrants
Issued via preferential allotment · Conversion pending
PR
Promoter Group
65.21% holding
Steady post-pref holding — aligned with long-term value creation. Down from 71.53% pre-pref.
Key Re-Rating Catalysts
Smartphone launch announcement (Phase 2)
SFL integration & hearing aid retail revenue — Q1 FY27 closing
US FDA Registration secured (Apr 2026) — triggers export-led growth, OEM partnerships, and margin expansion
₹50 Cr Army tender outcome (LED defence supply)
JNPT free-zone facility operationalisation — Middle East + US exports
Pref lock-in lapsed — no supply hit yet; Mukul Agrawal holding firm
11 · Investment Considerations
Positives & Risks — Eyes Wide Open
📈
Multi-Vertical Revenue Mix
Revenue diversified across LED (49%), Hearing Aids (35%), Mobile (15%). No single segment dominates — reduces revenue concentration risk materially.
⚠️
Working Capital Stress
Receivable days 73→128 (FY24→FY25). Working capital days 38→163. Government project cycles extend to 120+ days. Cash conversion cycle widening is the key watch point.
🔑
Philips Brand + Distribution Moat
Exclusive Philips license via TPV gives OSEL 150+ years of brand equity. 120 distributors + 650 service centres built in just 4 months — rare execution pace.
📱
Mobile Execution Risk
Feature phone market dominated by JioPhone, Samsung & Chinese brands. Consumer pull vs. retailer push unproven at volume. Phase 2 (smartphones) timeline uncertain.
🏆
Institutional Validation at ₹340
Mukul Agrawal entered via pref at ₹340; 6-month lock-in lapsed Mar 2026 — no supply has hit market. Both Mukul Agrawal and promoters holding firm.
🌍
Geopolitical & Supply Chain
LED drivers, hearing aid chips and phone components largely imported from China/Taiwan. INR depreciation directly hits margins. Regional tensions add supply uncertainty.
💰
Profitable & High ROE
3Y PAT CAGR 111%; ROE 30%, ROCE 31%. Rare combination for an SME at this stage. EBITDA margins expanding 5% (FY21) → 18% (TTM) as operating leverage kicks in.
📉
Promoter Dilution Watch
Promoter holding fell 71.53%→65.21% post-pref. Further dilution without matching revenue growth could signal concern. Monitor quarterly shareholding pattern closely.
🔗
Adjacent Segment Synergy
LED → Hearing Aid → Mobile share electronics manufacturing DNA, B2G/B2B distribution, and regulatory know-how — each new vertical entry is cheaper and lower-risk.
🎧
Hearing Aid Retail Competition
Global Big 5 (Sonova, Starkey, Siemens, Amplifon, Oticon) dominate retail via audiologist relationships. OSEL's retail brand equity is an early-stage test.
🚀
Defence + Export Optionality
₹50 Cr Army tender pending; JNPT free-zone facility targeting Middle East + US exports. New defence & broadcast hires deepen pipeline. Not priced in yet.
📊
SME Platform Liquidity
Thin volumes, wide bid-ask spreads. Stock already fell 40% from ₹835 peak. Institutional exits or news-driven corrections can be sharp and swift. Position sizing matters.
12 · Important Notice
Please Read Carefully
This presentation is prepared for educational and informational purposes only. It does not constitute investment advice, a buy/sell recommendation, a solicitation, or a research report as defined under SEBI (Research Analysts) Regulations, 2014.
Investing in SME-listed securities involves significant risks including limited liquidity, higher volatility, lower regulatory disclosures, and concentration risk. Past performance is not indicative of future returns.
All data, figures, and estimates herein are sourced from publicly available information (NSE filings, Screener, company presentations, concall transcripts). Forward-looking estimates are indicative only. Readers must conduct independent due diligence and consult a SEBI-registered investment advisor before making any investment decision.
Report Date
March 2026
Exchange
NSE SME
OSELDEVICE
Market Cap (Updated)
₹899 Cr
CMP (Updated)
₹508